SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-021626
Filing Date
2021-11-04
Accepted
2021-11-04 09:01:13
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20211104.htm   iXBRL 8-K 37722
2 EX-99.1 a991pressreleasedatednovem.htm EX-99.1 111903
6 x4logo.jpg GRAPHIC 9468
  Complete submission text file 0001628280-21-021626.txt   316847

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20211104.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20211104_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20211104_pre.xml EX-101.PRE 13731
7 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20211104_htm.xml XML 11812
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 211378410
SIC: 2836 Biological Products, (No Diagnostic Substances)